BMRN FY2025 EPS Forecast Raised by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald raised its FY2025 earnings per share estimate for BioMarin Pharmaceutical Inc. from $3.78 to $4.02, with a future estimate for FY2026 set at $4.81.
• The average rating for BioMarin stock is currently a Moderate Buy, with thirteen analysts giving a Buy rating and a price target averaging $93.26.
• BioMarin has seen significant interest from hedge funds, with institutional ownership at approximately 98.71% of the company's stock.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) - Equities research analysts at Cantor Fitzgerald raised their FY2025 earnings per share estimates for BioMarin Pharmaceutical in a report issued on Tuesday, October 14th. Cantor Fitzgerald analyst O. Brayer now expects that the biotechnology company will post earnings per share of $4.02 for the year, up from their previous estimate of $3.78. The consensus estimate for BioMarin Pharmaceutical's current full-year earnings is $3.15 per share. Cantor Fitzgerald also issued estimates for BioMarin Pharmaceutical's FY2026 earnings at $4.81 EPS.

Several other equities analysts have also commented on BMRN. HC Wainwright initiated coverage on BioMarin Pharmaceutical in a research note on Monday, September 8th. They set a "neutral" rating and a $60.00 price target on the stock. Raymond James Financial initiated coverage on BioMarin Pharmaceutical in a research note on Wednesday, September 3rd. They set an "outperform" rating and a $85.00 price target on the stock. Zacks Research lowered BioMarin Pharmaceutical from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, August 13th. Wolfe Research set a $95.00 price target on BioMarin Pharmaceutical and gave the company an "outperform" rating in a research note on Tuesday, July 15th. Finally, Guggenheim raised their price target on BioMarin Pharmaceutical from $101.00 to $106.00 and gave the company a "buy" rating in a research note on Wednesday, August 6th. Thirteen analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, BioMarin Pharmaceutical presently has an average rating of "Moderate Buy" and an average target price of $93.26.

BioMarin Pharmaceutical Stock Performance

Shares of BioMarin Pharmaceutical stock opened at $53.09 on Thursday. The firm has a market cap of $10.19 billion, a P/E ratio of 15.75, a P/E/G ratio of 0.73 and a beta of 0.33. The company has a current ratio of 5.56, a quick ratio of 3.60 and a debt-to-equity ratio of 0.10. BioMarin Pharmaceutical has a 12 month low of $51.56 and a 12 month high of $73.51. The stock's fifty day moving average price is $55.87 and its 200-day moving average price is $57.79.

Hedge Funds Weigh In On BioMarin Pharmaceutical

Several institutional investors and hedge funds have recently added to or reduced their stakes in BMRN. Farther Finance Advisors LLC grew its stake in BioMarin Pharmaceutical by 95.9% in the first quarter. Farther Finance Advisors LLC now owns 431 shares of the biotechnology company's stock valued at $29,000 after purchasing an additional 211 shares during the last quarter. GAMMA Investing LLC boosted its holdings in BioMarin Pharmaceutical by 154.0% in the first quarter. GAMMA Investing LLC now owns 3,129 shares of the biotechnology company's stock worth $221,000 after acquiring an additional 1,897 shares in the last quarter. Fifth Third Bancorp boosted its holdings in BioMarin Pharmaceutical by 76.2% in the first quarter. Fifth Third Bancorp now owns 2,381 shares of the biotechnology company's stock worth $168,000 after acquiring an additional 1,030 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its holdings in BioMarin Pharmaceutical by 92.2% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 44,584 shares of the biotechnology company's stock worth $3,152,000 after acquiring an additional 21,383 shares in the last quarter. Finally, Exchange Traded Concepts LLC boosted its holdings in BioMarin Pharmaceutical by 5.2% in the first quarter. Exchange Traded Concepts LLC now owns 19,796 shares of the biotechnology company's stock worth $1,399,000 after acquiring an additional 979 shares in the last quarter. Hedge funds and other institutional investors own 98.71% of the company's stock.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.